CannPal Animal Therapeutics Limited announced it has received ethics approval to advance its clinical development plans for CPAT-01, a pain control being developed for cats and dogs. Phase 1B is a continuation of research into CannPal's lead drug candidate, CPAT-01, an innovative cannabis-derived pain control for companion animals. The Company recently announced the completion of Phase 1A of the Pharmacokinetic and Safety study, and was pleased to note that the formulations used in the study were well-tolerated, with no adverse events reported and significant levels of absorption achieved. The ethics approval is for Phase 1B of this study, which will involve 48 dogs and is set to commence this month. Phase 1B endpoints are to assess additional pharmacokinetic and safety parameters and assess tolerability at 5x the estimated dose. The Company will also be completing pathway-focused gene expression analysis as part of this study, using laboratory-verified PCR (Polymerase Chain Reaction) assays to identify potential underlying mechanisms of action for treating pain and inflammation in dogs. CannPal is in the final stage of completing the protocols for Phase 1B and has the necessary clinical trial material ready to conduct the study, which was imported earlier in 2018. The Company reported a quick turnaround time between the completion of Phase 1A in May and further research commencing in August.